Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Item Justin Atangwho
Total Records ( 2 ) for Item Justin Atangwho
  Patrick Ekong Ebong , Item Justin Atangwho , Eyong Ubana Eyong and Godwin Eneji Egbung
  Polyherbal therapy is said to be a current pharmacological principle having the advantage of producing maximum therapeutic efficacy with minimum side effects. We assessed the antidiabetic efficacy and hence the impact on biochemical indices of toxicity by a combination of extracts from neem and bitterleaf. Thirty rats, 25 diabetic and 5 non-diabetic rats, were used for the study. The diabetic rats were divided equally into five groups and respectively treated: saline (diabetic control), extracts from neem and bitterleaf combined, neem only, bitterleaf only and chlorpropamide for a 24 day period. After oral administration of the first dose of extract (400 mg kg¯1 b.w.) and chlorpropamide (4.286 mg kg¯1 b.w.), blood glucose was monitored in vivo at various time intervals for 9 h, thereafter daily administration continued for 24 days. Whereas single dose treatment with neem only showed peak reduction (28.56%) an hour after, treatments with combined extracts, bitterleaf and chlorpropamide had their peak reductions all at the 7th hour (24.78, 47.31 and 60.51%, respectively). Percentage reductions in blood glucose relative to their initial values at the end of treatment were 71.05, 44.95, 88.63 and 75.83 for combined extract, neem, bitterleaf and chlorpropamide respectively. The decrease in blood glucose for the groups treated with combined extracts and bitterleaf only compared well (p<0.01) with chlorpropamide and non diabetic control, but not with neem alone. Determination of markers of hepatotoxicity in serum including GPT and GOT activities, total protein, albumin and urea indicated that, of the four treatments, neem provides the best protection against hepatic dysfunction. In the group treated with combined extracts these alternate selective advantages of neem and bitterleaf were expressed as a positive synergy, hence more beneficial than individual treatments.
  Godwin Eneji Egbung , Ochuole Diana Odey and Item Justin Atangwho
  Objective: To investigate the renoprotective potentials of Vernonia calvoana extract (VCE) in acetaminophen treated Wistar rats. Materials and Methods: Thirty-five male Wistar rats (100-150 g) were randomly assigned to 5 groups of 7 rats each. Group 1 (normal control) received normal saline, group 2 received normal saline after oral administration of 2 g kg–1 b.wt. of acetaminophen, groups 3 and 4 were administered 200 and 400 mg kg–1 b.wt. of VCE, respectively after pre-treatment with acetaminophen. Group 5 was administered 100 mg kg–1 b.wt., of Vitamin E. All treatments were given orally and study lasted for 21 days thereafter blood was collected for measurement of kidney function biomarkers. One-way analysis of variance was used for analysis followed by post hoc multiple comparisons and SPSS. Results: The results showed increased serum sodium concentration in group 3 and 4 administered VCE when compared with the acetaminophen treated control, unlike the Vit E supplemented group which showed a decrease (p<0.001). Conversely, serum potassium and urea concentrations were decreased in the VCE treated groups compared to the acetaminophen treated control (p<0.001). Further, serum creatinine, a notable marker of kidney function was decreased in VCE treated groups in tandem Vit. E supplemented group when compared to acetaminophen-treated control. Conclusion: It was concluded that extracts of Vernonia calvoana leaves potently ameliorated imbalance in kidney function biomarkers induced by acetaminophen, hence may possesses renoprotective potentials.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility